{"entity":{"id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","aka":[],"tldr":"A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT07038096 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 350 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-09. Interventions recorded: ZG006, ZG005. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07038096","url":"https://clinicaltrials.gov/study/NCT07038096"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zg006"],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07038096","phase":"1/2","setting":"A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":350,"outcomes":[]},"route":"/trials/nct07038096/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}